What is Biological E?
Biological E. Limited operates as a premier biopharmaceutical entity, specializing in the end-to-end development, manufacturing, and supply of vaccines and injectable pharmaceuticals. The company distinguishes itself through a robust commitment to affordable healthcare, utilizing advanced manufacturing capabilities to address infectious diseases on a global scale. By maintaining rigorous regulatory standards and fostering international partnerships, Biological E has established itself as a vital supplier for both domestic and global markets, ensuring that critical medical interventions remain accessible to diverse populations.
How much funding has Biological E raised?
Biological E has raised a total of $5M across 1 funding round:
Grant
$5M
Grant (2020): $5M with participation from Coalition for Epidemic Preparedness Innovations
Key Investors in Biological E
Coalition for Epidemic Preparedness Innovations
A global partnership of public, private, philanthropic, and civil society organizations that finances and coordinates the development of vaccines against high-epidemic potential diseases.
What's next for Biological E?
With this major enterprise-level funding, Biological E is poised to accelerate its research and development pipeline while expanding its manufacturing footprint. The strategic allocation of these resources will likely focus on scaling production capacity to meet the rising demand for specialty biologic products and enhancing the company's ability to respond to emerging health threats. As the firm moves into its next phase of growth, the focus will remain on optimizing supply chain resilience and deepening its integration into global health initiatives, ensuring long-term sustainability and continued innovation in the biopharmaceutical sector.
See full Biological E company page
